Dna Or Rna Fragments Or Modified Forms Thereof (e.g., Genes, Etc.) Patents (Class 536/23.1)
  • Patent number: 9764013
    Abstract: The invention provides a bacterium containing a polynucleotide comprising a nucleic acid encoding a heterologous antigen, as well as fusion protein partners. Also provided are vectors for mediating site-specific recombination and vectors comprising removable antibiotic resistance genes.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: September 19, 2017
    Assignee: ADURO BIOTECH, INC.
    Inventors: Thomas W. Dubensky, Jr., Justin Skoble, Peter M. Lauer, David N. Cook
  • Patent number: 9765109
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: September 19, 2017
    Assignee: Geron Corporation
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz
  • Patent number: 9753035
    Abstract: The present invention relates to DNA sequences from regions of copy number change on chromosome 20. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: September 5, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Daniel Pinkel, Donna G. Albertson, Joe W. Gray
  • Patent number: 9745577
    Abstract: Disclosed herein are methods, compositions, polynucleic acid polymers, assays, and kits for inducing processing of a partially processed mRNA transcript to remove a retained intron to produce a fully processed mRNA transcript that encodes a full-length functional form of a protein. Also described herein are methods and compositions for treating a disease or condition characterized by impaired production of a full-length functional form of a protein or for treating a disease or condition characterized by a defective splicing in a subject.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: August 29, 2017
    Assignee: UNIVERSITY OF SOUTHAMPTON
    Inventors: Igor Vorechovsky, Jana Kralovicova
  • Patent number: 9745574
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: August 29, 2017
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
  • Patent number: 9745636
    Abstract: The invention relates to the SWI5 gene, the corresponding RNA, specific probes, primers and oligonucleotides related thereto and their use in diagnostic assays to detect and/or discriminate between fungal and yeast species.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: August 29, 2017
    Assignee: National University of Ireland, Galway
    Inventors: Thomas Gerard Barry, Majella Maher, Terry James Smith, Marcin Jankiewicz, Louise O'Connor, Nina Tuite, Sinead Lahiff
  • Patent number: 9744224
    Abstract: A immunogenic composition is provided for use in methods for treating or preventing the development of a cancer, comprising a nucleic acid sequence encoding a cancer antigen and a nucleic acid sequence encoding fibroblast activation protein (FAP). In one embodiment, the composition comprises a vector comprising a first expression cassette comprising a nucleic acid sequence encoding an antigen of a, operatively linked to an expression control sequence that directs the expression of the antigen in a mammalian host cell. The composition further contains a vector comprising a second expression cassette comprising a nucleic acid sequence encoding fibroblast activation protein (FAP) operatively linked to an expression control sequence directing the expression of FAP in a mammalian host cell. In one embodiment, the cancer is one in which tumor progression depends on the fibroblasts expressing fibroblast activation protein (FAP).
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: August 29, 2017
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Hildegund C. J. Ertl, Ying Zhang
  • Patent number: 9725712
    Abstract: The invention relates to a tomato plant, wherein the fruits of which have an improved shelf-life as compared to the fruits of a wild type tomato plant, wherein the genetic determinant causative of the improved shelf life trait is a mutation in the hp2 gene. The increased shelf-life may comprise a fruit that shows normal ripening having a fruit firmness at red ripe harvest that is increased by at least 31%, preferably by at least 42%, more preferably by at least 52%, even more preferably by at least 60%, most preferably by at least 70% as compared to a fruit having similar genetic background that lacks the trait of the invention.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 8, 2017
    Assignee: RIJK ZWAAN ZAADTEELT EN ZAADHANDEL B.V.
    Inventors: Cornelis Maria Petrus Van Dun, Pieter Martijn Eggink, Dorthe Bettina Drager
  • Patent number: 9719097
    Abstract: The present disclosure discloses a vector that can be used for both cyanobacteria and E. coli, which contains, sequentially, a pUC replication origin as a replication origin; a spectinomycin-resistant gene as a selection marker; and a promoter selected from a group consisting of a trc promoter, a tetA promoter or a modified tetA promoter, a BAD promoter and a cbbL promoter. An industrially useful substance may be produced effectively using a host cell transformed with the vector. Also, the vector may be used to insert a variety of target genes through simple combination and, as a result, various vectors can be prepared effectively.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 1, 2017
    Assignee: Korea Institute of Science and Technology
    Inventors: Han Min Woo, Jun Won Chwa, Youngsoon Um, Gyeong Taek Gong, Yunje Kim
  • Patent number: 9717685
    Abstract: The invention provides nanoparticles containing a nucleic acid nanostructure, of defined shape and size, linked to a hydrophobic moiety and coated by lipids, compositions comprising the nanoparticles, and methods of producing and methods of using the nanoparticles.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 1, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: William M. Shih, Steven Perrault
  • Patent number: 9714410
    Abstract: It is an object of the present invention to allow a cell to produce a protein at a high level using a medium containing an enzymatic degradation product of fish meat or a fish meat extract. A method of culturing a cell comprising starting culturing in an initial medium and feeding at least once a feed medium to the initial medium during culturing, wherein at least one of the initial medium or the feed medium contains an enzymatic degradation product of fish meat or a fish meat extract added thereto. A method of producing a protein of interest using the above culture method.
    Type: Grant
    Filed: December 26, 2005
    Date of Patent: July 25, 2017
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Susumu Goto, Shohei Kishishita, Shinya Takuma, Chikashi Hirashima
  • Patent number: 9708373
    Abstract: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: July 18, 2017
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Adolfo Garcia-Sastre, Peter Palese, John Steel, Anice C. Lowen
  • Patent number: 9695211
    Abstract: Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically stable H-phosphonate moiety with a nucleoside/nucleotide.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 4, 2017
    Assignee: WAVE LIFE SCIENCES JAPAN, INC.
    Inventors: Takeshi Wada, Mamoru Shimizu
  • Patent number: 9695424
    Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: July 4, 2017
    Assignee: SomaLogic, Inc.
    Inventors: Nebojsa Janjic, Daniel W. Drolet, Amy D. Gelinas, Chi Zhang, Michael Vrkljan
  • Patent number: 9675663
    Abstract: A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: June 13, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack Roth, David Stewart, Charles Lu, Ignacio I. Wistuba, Shaoyu Yan, Maria I. Nunez
  • Patent number: 9671340
    Abstract: The invention relates to a method for acquiring data in order to determine organ function, in particular the liver or kidney function, comprising one or more polymethine fluorescent dyes having a fluorescence emission maximum, measured in ethanol, of less than or equal to 820 nm, and to the use of dyes as markers for acquiring data in order to determine the organ function. The invention further relates to a kit for determining an organ function with a marker dye, and to a device for acquiring data in the method.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: June 6, 2017
    Assignee: SMARTDYELIVERY GMBH
    Inventors: Michael Bauer, Falk A. Gonnert, Peter Recknagel
  • Patent number: 9657342
    Abstract: The invention provides methods for determining aneuploidy and/or fetal fraction in maternal samples comprising fetal and maternal cfDNA by massively parallel sequencing. The method comprises a novel protocol for preparing sequencing libraries that unexpectedly improves the quality of library DNA while expediting the process of analysis of samples for prenatal diagnoses.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: May 23, 2017
    Assignee: Verinata Health, Inc.
    Inventors: Richard P. Rava, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Brian Kent Rhees
  • Patent number: 9645140
    Abstract: Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: May 9, 2017
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Brian Agnew, Kyle Gee, Tamara Nyberg
  • Patent number: 9636414
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 2, 2017
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • Patent number: 9624496
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 18, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie
  • Patent number: 9624546
    Abstract: Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: April 18, 2017
    Assignee: Myriad Genetics, Inc.
    Inventors: Julian R. Sampson, Jeremy Peter Cheadle
  • Patent number: 9598703
    Abstract: An isolated linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods for producing and purifying this nucleic acid molecule, and use of the same for therapeutic purposes are also provided.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: March 21, 2017
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE; UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTÉ DE LAD RECHERCHE MÉDICALE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
    Inventors: Luis Garcia, Cyriaque Beley, Thomas Voit, Robert Michael Kotin, Lina Li
  • Patent number: 9592301
    Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: March 14, 2017
    Inventors: Kenneth Michael Hargreaves, John Gordon Bruno
  • Patent number: 9573962
    Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and/or reducing the risk of microbial infections in humans and animals.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 21, 2017
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Shili Chen, Marco DeVivo, Rongliang Lou, Brian T. Wimberly
  • Patent number: 9567338
    Abstract: Pyrazolo[3,4-d]pyrimidine compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as a process for preparing these compounds, compositions comprising them and their use as medicaments.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 14, 2017
    Assignee: LABORATORIOS DEL DR. ESTEVE S.A.
    Inventors: Maria Rosa Cuberes-Altisent, Jordi Corbera-Arjona, Jose Luis Diaz-Fernandez, Carmen Almansa-Rosales
  • Patent number: 9567591
    Abstract: This invention generally relates to a method for developing, generating and selecting human embryonic stem (hES)-like pluripotent cells using transgenic expression of intronic microRNA-like RNA agents. More particularly, the present invention relates to a method and composition for generating a non-naturally occurring intron and its intronic components capable of being processed into mir-302-like RNA molecules in mammalian cells and thus inducing certain specific gene silencing effects on differentiation-related and fate-determinant genes of the cells, resulting in reprogramming the cells into a pluripotent embryonic stem (ES)-cell-like state. The ES-like cells so obtained are strongly express hES cell markers, such as Oct3/4, SSEA-3 and SSEA-4, and can be guided into various tissue cell types by treating certain hormones and/or growth factors under a feeder-free cell culture condition in vitro, which may be used for transplantation and gene therapies.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: February 14, 2017
    Assignees: MELLO BIOTECHNOLOGY, INC., UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Shi-Lung Lin, Shao-Yao Ying, David Ts Wu
  • Patent number: 9562076
    Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: February 7, 2017
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT-HEIDELBERG (Rektorat)
    Inventors: Walter Mier, Stephan Urban
  • Patent number: 9545383
    Abstract: The disclosure is directed to enabling reversible, on-demand remote control of blood clotting and clot dissolution. In one embodiment, a laser at one wavelength triggers release of a DNA thrombin inhibitor from one nanorod, which acts as an anticoagulant to stop blood clotting. Another wavelength triggers release of a specific antidote, which reverses the effect of the thrombin inhibitor, restoring blood clotting.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 17, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Kimberly Hamad-Schifferli, Salmaan H. Baxamusa, Helena de Puig Guixe
  • Patent number: 9546112
    Abstract: Methods for increasing the efficiency of target tissue penetration of an adeno-associated virus (AAV) vector in a patient are provided. In some aspects, the methods involve inhibiting the interaction of the serum protein galectin 3 binding protein (G3BP) with AAV vector. Further provided are methods for reducing tissue distribution of a virus or for neutralizing a virus harbored by an organ destined for transplant, or newly transplanted, by administering a composition comprising G3BP.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: January 17, 2017
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE, GÉNÉTHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6), INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Thomas Voit, Luis Garcia, Jérôme Denard, Fedor Svinartchouk
  • Patent number: 9539323
    Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: January 10, 2017
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Vikas P. Sukhatme, Jian-Guo Ren
  • Patent number: 9534260
    Abstract: This application provides materials and methods for the detection of the aad-12 gene and event pDAB4472-1606 in biological samples derived from plants.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: January 3, 2017
    Assignee: Dow AgroSciences LLC
    Inventors: Chandra-Shekara A. Channabasavaradhya, Andrew Greenwald
  • Patent number: 9522948
    Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 20, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
  • Patent number: 9512483
    Abstract: The present invention provides for a method to monitor the health of a subject. The method includes obtaining a test sample from the patient. A first probe specific for a CpG promoter region of a biomarker selected from p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample. The probe contacts the test sample. The DNA of interest from the test sample is isolated. A second stage probe specific for a second CpG promoter region of a biomarker selected from p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample to form a second stage PCR product. The DNA is analyzed for hypermethylation of the promoter region for at least one of p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: December 6, 2016
    Assignee: LOVELACE RESPIRATORY RESEARCH INSTITUTE
    Inventor: Steven A. Belinsky
  • Patent number: 9512164
    Abstract: Modified nucleic acids are described herein, including pharmaceutical compositions comprising the modified nucleic acids, and methods of using the modified nucleic acids.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: December 6, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Patent number: 9506111
    Abstract: The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having a 3?-terminal nucleotide complementary to only one variant of the target sequence and having at least one nucleotide with a base covalently modified at the exocyclic amino group, wherein the allele-specific oligonucleotide is extended by a nucleotide-incorporating biocatalyst predominantly when hybridized to the variant of the target sequence for which it has said complementary 3?-terminal nucleotide.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: November 29, 2016
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Stephen G. Will, Alison Tsan, Nicolas Newton
  • Patent number: 9497945
    Abstract: Non-human animals comprising a human or humanized DPP4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous Dpp4 gene with a human or humanized DPP4 gene, or non-human animals comprising a human or humanized DPP4 gene in addition to the endogenous Dpp4 gene are described. Non-human animals comprising a human or humanized DPP4 gene under control of human or non-human DPP4 regulatory elements is also provided, including non-human animals that have a replacement of non-human Dpp4-encoding sequence with human DPP4-encoding sequence at an endogenous non-human Dpp4 locus. Non-human animals comprising human or humanized DPP4 gene sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided. Methods for making and using the non-human animals are described.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: November 22, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Alexander Mujica
  • Patent number: 9499815
    Abstract: The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: November 22, 2016
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Burghardt Wittig, Manuel Schmidt, Janine Loehr
  • Patent number: 9493832
    Abstract: Methods of detecting sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more microRNAs associated with sepsis are also provided. Compositions and kits are also provided.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: November 15, 2016
    Assignee: Cepheid
    Inventors: David Vilanova, David H. Persing, Olivier Delfour, Bernard Michot
  • Patent number: 9493529
    Abstract: The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant protein. Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: November 15, 2016
    Assignee: Sanofi
    Inventors: Francis Blanche, Beatrice Cameron, Tarik Dabdoubi, Frederique Dol-Gleizes, Pierre Fons, Catherine Prades, Jean-Pascal Herault
  • Patent number: 9493547
    Abstract: The present invention provides polypeptides that bind to immunoglobulin G and methods for their use.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 15, 2016
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: David Baker, Eva-Maria Strauch, Sarel Jacob Fleishman
  • Patent number: 9493836
    Abstract: Disclosed is a method for the diagnosis, and/or the classification, of a hematological disorder, including the steps of: a). measuring, the expression level of at least the genes of a sub-group of 6 genes, b). comparing the expression level of each genes measured in step a)., with the expression level of the same genes in healthy control sample, and c). determining the status of the biological sample.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 15, 2016
    Assignee: UNIVERSITE FRANCOIS RABELAIS DE TOURS
    Inventors: Olivier Herault, Christine Vignon
  • Patent number: 9486533
    Abstract: Provided herein are aptamers and pharmaceutical compositions comprising the same. In some embodiments, the aptamer selectively binds a protein of interest such as an extracellular receptor protein of interest (e.g., a cancer cell extracellular receptor protein, which may be differentially expressed in some embodiments). In some embodiments, the aptamer is directly linked by covalent bonding (e.g., via a geminal diamine linkage) to from 2 to 10 toxin compounds. Also provided herein is a method of selecting an aptamer that specifically binds to a protein expressed by a cell of interest, wherein in some embodiments the aptamer comprises at least one binding site for one or more active compounds. In some embodiments, primer regions flanking the variable region of the aptamers in the pool contains from 1 to 10 mismatches with respect to said forward or reverse primer.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: November 8, 2016
    Assignee: Wake Forest University Health Sciences
    Inventor: William H. Gmeiner
  • Patent number: 9481873
    Abstract: The present invention relates to isolated polypeptides having ferulic acid esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: November 1, 2016
    Assignee: Novozymes A/S
    Inventors: Christel Thea Joergensen, Mary Ann Stringer, Eva Holm Hansen, Dominique Aubert Skovlund, Kristian Bertel Roemer Moerkeberg Krogh
  • Patent number: 9458505
    Abstract: A method of diagnosing Cowden syndrome (CS) and Cowden-like Syndrome (CLS) is described. The method includes diagnosing CS and CLS in a subject by identifying a decrease in expression of the KILLIN gene, or by identifying hypermethylation of the KILLIN promoter region. Kits for diagnosing CS and CLS by identifying subjects having KILLIN promoter region hypermethylation and primers specific for a methylated KILLIN promoter region are also described.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 4, 2016
    Assignee: The Cleveland Clinic Foundation
    Inventor: Charis Eng
  • Patent number: 9458514
    Abstract: The present invention use of to a portion of the RPS7 gene or its corresponding mRNA in a diagnostic assay for fungal and yeast species and sequences for use in such assays and methods.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: October 4, 2016
    Assignee: National University of Ireland, Galway
    Inventors: Thomas Gerard Barry, Terence James Smith, Majella Maher
  • Patent number: 9453835
    Abstract: The present invention relates to a method for screening a modulator of a TMEM16 family member, which comprises the following steps: (1) treating cells expressing the TMEM16 family member with a candidate of the modulator, and (2) determining whether the candidate alters distribution of a lipid selected from phosphatidylserine, phosphatidylcholine, and galactosylceramide in plasma membrane of the cells, wherein a candidate which increases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as a modulator enhancing a function of the TMEM16 family member, and a candidate which decreases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as a modulator suppressing a function of the TMEM16 family member, and a candidate which increases distribution of phosphatidylcholine or galactosylceramide in the inner leaflet of plasma membrane compared to control is selected as a modulator enhancing a function of
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: September 27, 2016
    Assignee: KYOTO UNIVERSITY
    Inventors: Shigekazu Nagata, Jun Suzuki, Toshihiro Fujii
  • Patent number: 9452219
    Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: September 27, 2016
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Paula J. Bates, Mohammad Tariq Malik, Kyung A. Kang
  • Patent number: 9453219
    Abstract: The present invention relates to a method and composition for generating a non-naturally occurring intron and its components capable of being processed into small hairpin RNA (shRNA) and/or microRNA (miRNA) molecules by skin cells and thus inducing specific gene silencing effects on skin pigment-related genes and/or aging-causing genes in the cells. The gene silencing effects so obtained are not only useful for lightening and whitening skin colors but also useful for suppressing unwanted aging gene activities in skins.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: September 27, 2016
    Assignee: MELLO BIOTECH TAIWAN CO., LTD.
    Inventors: Shi-Lung Lin, David TS Wu
  • Patent number: 9434775
    Abstract: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: September 6, 2016
    Assignees: Perseus Proteomics Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Yoshitaka Hippo, Hirokazu Taniguchi, Yong xin Chen, Shumpei Ishikawa, Shin-ichi Fukumoto, Takahiro Shimamura, Naoka Kamimura, Ying qiu Guo, Shogo Yamamoto, Yukio Ito, Hirotaka Ito, Toshihiko Ohtomo
  • Patent number: 9433666
    Abstract: The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of DO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: September 6, 2016
    Assignee: IO Bioech ApS
    Inventors: Mads Hald Andersen, Per Thor Straten